glp 1 agonist eli lilly Lilly's orforglipron: a new oral GLP-1 therapy | Thomas Fessard posted on the topic What's Coming Next for GLP-1

Because no study has ever administered cagrilintide and tirzepatide to comparable subjects and measured them against each other , any statement that one is stronger, better, or more effective than the other is inference, not measurement

Hyperuricemia induces endothelial dysfunction

Comment: Commenters requested CMS provide coding guidance on the appropriate device billed under HCPCS code C9761

For public health programs like Medicare, expanding access to these drugs could result in significant savings by reducing the prevalence of conditions like diabetes, heart disease, and stroke, as well as potential benefits for depression, sleep apnea, Alzheimers, and substance use disorders

Ma Y, Lee E, Yoshikawa H, Noda T, Miyamoto J, Kimura I, et al

B.AkkolE